Goldman Sachs
EWTX icon

Goldman Sachs’s Edgewise Therapeutics EWTX Stock Holding History

Goldman Sachs’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69,800
Closed -$1.73M – 6642
2025
Q4 		$1.73M Buy
+69,800
New +$1.4M ﹤0.01% 4719

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's EWTX Position: Q2 2026 in Review

Goldman Sachs reduced its Edgewise Therapeutics (EWTX) stake by 4.8% in Q2 2026, selling an estimated $1.05M and leaving 599,469 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

Goldman Sachs first reported a position in EWTX in Q1 2021 and has held it in 20 quarters since. The position peaked at $31.9M in Q1 2024. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Goldman Sachs held 599,469 shares of Edgewise Therapeutics worth $24.4M as of Q2 2026.
  • Goldman Sachs sold 30,351 Edgewise Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Edgewise Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2444 holding.
  • Goldman Sachs first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Goldman Sachs's Edgewise Therapeutics position peaked at $31.9M in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.